drugset / Trial / NCT04589429

Adding Nalbuphine for Control of Intrathecal Morphine Pruritus

NCT04589429

Phase 2 Unknown 70 enrolled Minia University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Intrathecal morphine causes intense itching which is very bothersome. Nalbuphine antagonizes this effect when given intravenously. This trial is to find out if nalbuphine added to intrathecal morphine has an effect on morphine related pruritus while still maintaining adequate analgesia.

Timeline

Start
2020-10-15
Primary completion
2021-03
Completion
2021-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nalbuphine Small molecule 2 mg Intrathecal
Comparator Morphine Other / unclassified 0.3 mg Intrathecal

Indications

No indication recorded.